A SARS-CoV-2 coronavirus nucleocapsid protein antigen-detecting lateral flow assay

Inexpensive, simple, rapid diagnostics are necessary for efficient detection, treatment, and mitigation of COVID-19. Assays for SARS-CoV2 using reverse transcription polymerase chain reaction (RT-PCR) offer good sensitivity and excellent specificity, but are expensive, slowed by transport to central...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Benjamin D. Grant, Caitlin E. Anderson, Luis F. Alonzo, Spencer H. Garing, John R. Williford, Ted A. Baughman, Rafael Rivera, Veronika A. Glukhova, David S. Boyle, Puneet K. Dewan, Bernhard H. Weigl, Kevin P. Nichols
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6d6a8db8cf6548dbb67de11f5199f595
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6d6a8db8cf6548dbb67de11f5199f595
record_format	dspace
spelling	oai:doaj.org-article:6d6a8db8cf6548dbb67de11f5199f5952021-11-18T06:34:40ZA SARS-CoV-2 coronavirus nucleocapsid protein antigen-detecting lateral flow assay1932-6203https://doaj.org/article/6d6a8db8cf6548dbb67de11f5199f5952021-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580225/?tool=EBIhttps://doaj.org/toc/1932-6203Inexpensive, simple, rapid diagnostics are necessary for efficient detection, treatment, and mitigation of COVID-19. Assays for SARS-CoV2 using reverse transcription polymerase chain reaction (RT-PCR) offer good sensitivity and excellent specificity, but are expensive, slowed by transport to centralized testing laboratories, and often unavailable. Antigen-based assays are inexpensive and can be rapidly mass-produced and deployed at point-of-care, with lateral flow assays (LFAs) being the most common format. While various manufacturers have produced commercially available SARS-Cov2 antigen LFAs, access to validated tests remains difficult or cost prohibitive in low-and middle-income countries. Herein, we present a visually read open-access LFA (OA-LFA) using commercially-available antibodies and materials for the detection of SARS-CoV-2. The LFA yielded a Limit of Detection (LOD) of 4 TCID50/swab of gamma irradiated SARS-CoV-2 virus, meeting the acceptable analytical sensitivity outlined by in World Health Organization target product profile. The open-source architecture presented in this manuscript provides a template for manufacturers around the globe to rapidly design a SARS-CoV2 antigen test.Benjamin D. GrantCaitlin E. AndersonLuis F. AlonzoSpencer H. GaringJohn R. WillifordTed A. BaughmanRafael RiveraVeronika A. GlukhovaDavid S. BoylePuneet K. DewanBernhard H. WeiglKevin P. NicholsPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Benjamin D. Grant Caitlin E. Anderson Luis F. Alonzo Spencer H. Garing John R. Williford Ted A. Baughman Rafael Rivera Veronika A. Glukhova David S. Boyle Puneet K. Dewan Bernhard H. Weigl Kevin P. Nichols A SARS-CoV-2 coronavirus nucleocapsid protein antigen-detecting lateral flow assay
description	Inexpensive, simple, rapid diagnostics are necessary for efficient detection, treatment, and mitigation of COVID-19. Assays for SARS-CoV2 using reverse transcription polymerase chain reaction (RT-PCR) offer good sensitivity and excellent specificity, but are expensive, slowed by transport to centralized testing laboratories, and often unavailable. Antigen-based assays are inexpensive and can be rapidly mass-produced and deployed at point-of-care, with lateral flow assays (LFAs) being the most common format. While various manufacturers have produced commercially available SARS-Cov2 antigen LFAs, access to validated tests remains difficult or cost prohibitive in low-and middle-income countries. Herein, we present a visually read open-access LFA (OA-LFA) using commercially-available antibodies and materials for the detection of SARS-CoV-2. The LFA yielded a Limit of Detection (LOD) of 4 TCID50/swab of gamma irradiated SARS-CoV-2 virus, meeting the acceptable analytical sensitivity outlined by in World Health Organization target product profile. The open-source architecture presented in this manuscript provides a template for manufacturers around the globe to rapidly design a SARS-CoV2 antigen test.
format	article
author	Benjamin D. Grant Caitlin E. Anderson Luis F. Alonzo Spencer H. Garing John R. Williford Ted A. Baughman Rafael Rivera Veronika A. Glukhova David S. Boyle Puneet K. Dewan Bernhard H. Weigl Kevin P. Nichols
author_facet	Benjamin D. Grant Caitlin E. Anderson Luis F. Alonzo Spencer H. Garing John R. Williford Ted A. Baughman Rafael Rivera Veronika A. Glukhova David S. Boyle Puneet K. Dewan Bernhard H. Weigl Kevin P. Nichols
author_sort	Benjamin D. Grant
title	A SARS-CoV-2 coronavirus nucleocapsid protein antigen-detecting lateral flow assay
title_short	A SARS-CoV-2 coronavirus nucleocapsid protein antigen-detecting lateral flow assay
title_full	A SARS-CoV-2 coronavirus nucleocapsid protein antigen-detecting lateral flow assay
title_fullStr	A SARS-CoV-2 coronavirus nucleocapsid protein antigen-detecting lateral flow assay
title_full_unstemmed	A SARS-CoV-2 coronavirus nucleocapsid protein antigen-detecting lateral flow assay
title_sort	sars-cov-2 coronavirus nucleocapsid protein antigen-detecting lateral flow assay
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/6d6a8db8cf6548dbb67de11f5199f595
work_keys_str_mv	AT benjamindgrant asarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT caitlineanderson asarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT luisfalonzo asarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT spencerhgaring asarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT johnrwilliford asarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT tedabaughman asarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT rafaelrivera asarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT veronikaaglukhova asarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT davidsboyle asarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT puneetkdewan asarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT bernhardhweigl asarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT kevinpnichols asarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT benjamindgrant sarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT caitlineanderson sarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT luisfalonzo sarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT spencerhgaring sarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT johnrwilliford sarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT tedabaughman sarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT rafaelrivera sarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT veronikaaglukhova sarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT davidsboyle sarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT puneetkdewan sarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT bernhardhweigl sarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT kevinpnichols sarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay
_version_	1718424484667457536

A SARS-CoV-2 coronavirus nucleocapsid protein antigen-detecting lateral flow assay

Ejemplares similares